Extended Data Fig. 7: Cathepsin inhibition by APICs in cellular assays.
From: Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins
a, b) CTSS inhibition in Raji cells (a) or human donor primary B cells (b) treated with αCD79 APIC or petesicatib, assessed by BMV109 quenched activity-based probe (qABP). c) CTSB inhibition in RT-4 bladder cancer cells assessed by BMV109 qABP. d) Dose-dependent CTSS inhibition in Raji cells treated with increasing concentration of αCD79 APIC assessed by BMV109 quenched activity-based probe (qABP).
